In this sense, an early introduction before the onset of neuropathy and vasculopathy could enhance the protective role of SGLT2-i, and vice versa, a late introduction in more advanced patients could highlight the detrimental effects perhaps linked to hypovolemic alterations. This evidence concerns the gene SLC5A2 and neuropathy.